Abstract Advanced clinical trials investigate the Psilocybe magic mushroom natural product psilocybin as a treatment against major depressive disorder. Currently, synthetic material is used to meet the demand for legitimate pharmaceutical purposes. Here, we report an in vitro approach to biocatalytically produce psilocybin on a solid‐phase matrix charged with five covalently bound biosynthetic...
Mood dysfunction is highly prevalent in Parkinson's disease (PD), a main predictor of functional decline, and difficult to treat-novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot...
Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive...
ABSTRACT Studies reporting novel therapeutic effects of psychedelic drugs are rapidly emerging. However, the reproducibility and reliability of these findings could remain uncertain for years. Here, we implemented a multi-institutional collaborative approach to define the robust and replicable effects of the psychedelic drug psilocybin on mouse behavior. Five laboratories performed the same...
To examine the relationship of acute psychedelic effects and measures of mental health with headache frequency in clinical trials of psilocybin in migraine and cluster headache.
The growing interest in psychedelic compounds for psychiatric disorders highlights the importance of well-designed preclinical studies [ 1 , 2 ]. In this context, Brownstein et al. [ 3 ] recently reported evidence of potential therapeutic benefits of psychedelic mushroom extract (PME) in the SAPAP3 knockout (KO) mouse model of obsessive-compulsive disorder (OCD)-like behaviours.
Psilocybin-assisted therapy (PAT) has gained recognition as an innovative intervention in hospice and palliative care, demonstrating potential in mitigating the psychological, spiritual, and existential distress experienced by patients with serious illnesses. This article explores the role of PAT within these care settings, emphasizing its influence on various dimensions of human suffering, as...
Psilocybin has various therapeutic effects in mental and psychological disorders, including depression and mood disorders, obsessive-compulsive disorders, substance addiction and anxiety. Pharmacodynamic properties of psilocybin depend on doses used and time after administration. The psilocybin dose range varies depending on whether it is used therapeutically or for recreational purposes in...
Psilocybin, a naturally occurring psychedelic compound in magic mushrooms, shows promise as a novel intervention with a single administration inducing rapid and long-lasting antidepressant effects. However, there are limited studies on the optimal dosing required for the beneficial effects of psilocybin given its side effects. To address this gap, we investigated in Wistar rats whether a single...
European PsychiatryApril 1, 2025P. Andres-Olivera, Janis V. de la Iglesia, E. Dominguez-Alvarez et al.
Introduction Psilocybin, a psychedelic compound, has shown potential in treating depression, especially in cases resistant to conventional treatments. This study systematically reviews the scientific literature to assess its efficacy and safety. Objectives The main objective of this study is to evaluate the therapeutic effects of psilocybin for the treatment of depressive disorder through a...